JP2020512336A5 - - Google Patents

Download PDF

Info

Publication number
JP2020512336A5
JP2020512336A5 JP2019552871A JP2019552871A JP2020512336A5 JP 2020512336 A5 JP2020512336 A5 JP 2020512336A5 JP 2019552871 A JP2019552871 A JP 2019552871A JP 2019552871 A JP2019552871 A JP 2019552871A JP 2020512336 A5 JP2020512336 A5 JP 2020512336A5
Authority
JP
Japan
Prior art keywords
amino acid
compound
zero
use according
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019552871A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020512336A (ja
JP7719590B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2018/050295 external-priority patent/WO2018176099A1/en
Publication of JP2020512336A publication Critical patent/JP2020512336A/ja
Publication of JP2020512336A5 publication Critical patent/JP2020512336A5/ja
Priority to JP2023034511A priority Critical patent/JP7795489B2/ja
Application granted granted Critical
Publication of JP7719590B2 publication Critical patent/JP7719590B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019552871A 2017-03-31 2018-03-29 Tlrアゴニストによる呼吸器感染症の治療 Active JP7719590B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023034511A JP7795489B2 (ja) 2017-03-31 2023-03-07 Tlrアゴニストによる呼吸器感染症の治療

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
AU2017901180A AU2017901180A0 (en) 2017-03-31 Treatment of respiratory infection
AU2017901180 2017-03-31
AU2017905124A AU2017905124A0 (en) 2017-12-21 Treatment of respiratory infection (2)
AU2017905128 2017-12-21
AU2017905128A AU2017905128A0 (en) 2017-12-21 Optimised compounds
AU2017905124 2017-12-21
AU2018900409A AU2018900409A0 (en) 2018-02-09 Treatment of respiratory infection (3)
AU2018900409 2018-02-09
PCT/AU2018/050295 WO2018176099A1 (en) 2017-03-31 2018-03-29 Treatment of respiratory infection with a tlr2 agonist

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023034511A Division JP7795489B2 (ja) 2017-03-31 2023-03-07 Tlrアゴニストによる呼吸器感染症の治療

Publications (3)

Publication Number Publication Date
JP2020512336A JP2020512336A (ja) 2020-04-23
JP2020512336A5 true JP2020512336A5 (enExample) 2021-04-08
JP7719590B2 JP7719590B2 (ja) 2025-08-06

Family

ID=63673872

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019552871A Active JP7719590B2 (ja) 2017-03-31 2018-03-29 Tlrアゴニストによる呼吸器感染症の治療
JP2023034511A Active JP7795489B2 (ja) 2017-03-31 2023-03-07 Tlrアゴニストによる呼吸器感染症の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023034511A Active JP7795489B2 (ja) 2017-03-31 2023-03-07 Tlrアゴニストによる呼吸器感染症の治療

Country Status (8)

Country Link
US (1) US20200147028A1 (enExample)
EP (1) EP3600374B1 (enExample)
JP (2) JP7719590B2 (enExample)
CN (2) CN110461351B (enExample)
AU (1) AU2018241248B2 (enExample)
ES (1) ES2979287T3 (enExample)
PL (1) PL3600374T3 (enExample)
WO (1) WO2018176099A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2811957C (en) 2010-09-22 2019-04-16 The University Of Melbourne Soluble tlr2 moiety for use in the treatment or prevention of respiratory conditions associated with infectious agents
IL275360B2 (en) * 2017-12-21 2023-10-01 Axelia Oncology Pty Ltd Optimal compounds
WO2019119069A1 (en) * 2017-12-21 2019-06-27 Ena Therapeutics Pty Ltd Administration of a tlr2 agonist for the treatment or prevention of a respiratory condition associated with an infectious agent
NZ783377A (en) * 2019-06-26 2026-03-27 Ena Respiratory Pty Ltd Pegylated novel molecules for agonising tlr2
WO2021042174A1 (en) * 2019-09-04 2021-03-11 Ena Therapeutics Pty Ltd Cancer treatment
JP2022546806A (ja) * 2019-09-04 2022-11-09 アクセリア オンコロジー ピーティーワイ リミテッド 癌免疫療法
US20230346829A1 (en) * 2020-05-11 2023-11-02 Revir, Inc. Compositions and methods for treating viral infections
AU2021278377A1 (en) * 2020-05-26 2022-12-15 Ena Respiratory Pty Ltd Treatment of coronavirus
AU2021294603A1 (en) * 2020-06-26 2022-12-15 Ena Respiratory Pty Ltd Branched lipid compounds
EP4395761A4 (en) * 2021-08-31 2025-10-01 Ena Respiratory Pty Ltd ALLERGY TREATMENT
AU2022338350A1 (en) * 2021-09-02 2024-02-29 Ena Respiratory Pty Ltd Formulation
CN114539356B (zh) * 2022-02-21 2023-06-09 中国人民解放军陆军军医大学 一种脂肽及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4119856A1 (de) 1991-06-17 1992-12-24 Hoechst Ag N-acyl-s-(2-hydroxyalkyl)-cysteine, deren herstellung sowie deren verwendung als zwischenprodukte zur herstellung von synthetischen immunadjuvantien und synthetischen impfstoffen
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
NZ536796A (en) * 2002-04-25 2007-03-30 Scripps Research Inst Treatment and prevention of pulmonary conditions comprising at least one lung surfactant polypeptide and at least one protease inhibitor, lipase inhibitor or an anti-oxidant
WO2005079419A2 (en) * 2004-02-17 2005-09-01 The Regents Of The University Of California Methods of treating immunopathological disorders
JP2008500289A (ja) * 2004-05-27 2008-01-10 ノヴォザイムズ グロペップ リミテッド 炎症性気道疾患の治療
WO2009137103A2 (en) * 2008-05-09 2009-11-12 Ourth Donald D Anti-cancer/anti-viral compounds and methods of use
WO2010115229A1 (en) 2009-04-09 2010-10-14 The University Of Melbourne Immunogenic composition and uses thereof
EA031379B1 (ru) * 2010-03-23 2018-12-28 Новартис Аг Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний
CA2811957C (en) * 2010-09-22 2019-04-16 The University Of Melbourne Soluble tlr2 moiety for use in the treatment or prevention of respiratory conditions associated with infectious agents
IN2014CN02581A (enExample) * 2011-10-06 2015-08-07 Immunovaccine Technologies Inc
US20170274068A1 (en) * 2014-09-12 2017-09-28 The University Of Melbourne Immunological reagent

Similar Documents

Publication Publication Date Title
JP7795489B2 (ja) Tlrアゴニストによる呼吸器感染症の治療
JP2023081969A5 (enExample)
JP6911044B2 (ja) 呼吸器系疾患の治療のためのグルココルチコイドとポリエチレングリコール修飾インターロイキン2の組合せ
JP2010502738A (ja) ナトリウムチャネル遮断剤および浸透圧調節物質での処置により粘膜水和および粘膜クリアランスを増強する方法
CN108350022A (zh) 聚乙二醇缀合的糖皮质激素前体药物及其组合物和方法
JP7439367B2 (ja) 最適化化合物
CN107412740A (zh) 聚乙二醇基肾上腺髓质素前药及其用途
WO2014138437A1 (en) Steroid conjugates
US10258634B2 (en) Ciclesonide for the treatment of airway disease in horses
AU2018370019A1 (en) Stable compositions of pegylated carfilzomib compounds
CN113966237A (zh) pHLIP®介导的皮质类固醇靶向病变组织
CN106488770A (zh) 用于治疗copd的福莫特罗和布地奈德的组合
WO2017180546A1 (en) Compositions and methods for treating and preventing lung disease
RU2010137337A (ru) Способы и композиции для лечения респираторных заболеваний
JP2006502086A (ja) 官能基を有するポリエチレングリコール賦形剤を用いた医薬用エアロゾル組成物
JP5459827B2 (ja) 慢性閉塞性肺疾患改善剤
AU2021251208A1 (en) Compositions and methods for treating and preventing lung disease
JP7254130B2 (ja) 結晶多形および医薬組成物
US20160331839A1 (en) Method for increasing the bioavailability of inhaled compounds
US20240269242A1 (en) Compositions and methods for treating and preventing lung disease
RU2013116520A (ru) Гиперсульфатированные дисахариды для лечения нарушений, связанных с эластазой
RU2494730C1 (ru) Ингаляционный препарат для лечения болезней органов дыхания, содержащий в качестве активных веществ микронизированный салметерол ксинофоат и микронизированный флутиказона пропионат и способ его получения
EP4392052A1 (en) Compositions and methods for treating and preventing lung disease
HK1246147B (en) Polyethylene glycol based prodrug of adrenomedullin and use thereof
KR20060118509A (ko) 신규 화합물